Eli Lilly: encouraging results for Retevmo
(CercleFinance.com) - Eli Lilly yesterday presented data from a phase 1/2 trial showing that Retevmo (selpercatinib) showed "encouraging" anti-tumor activity in the treatment of certain solid tumors.
The twelve cancer types treated included pancreatic, colon, breast, salivary, sarcoma, carcinoid, rectal neuroendocrine, small intestine, xanthogranuloma, ovarian, pulmonary carcinosarcoma, and unknown primary cancers, with responses observed in nine of them.
David Hyman, chief medical officer, oncology at Lilly, "These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that RET fusions are potentially actionable in a wide range of tumor types."
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The twelve cancer types treated included pancreatic, colon, breast, salivary, sarcoma, carcinoid, rectal neuroendocrine, small intestine, xanthogranuloma, ovarian, pulmonary carcinosarcoma, and unknown primary cancers, with responses observed in nine of them.
David Hyman, chief medical officer, oncology at Lilly, "These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that RET fusions are potentially actionable in a wide range of tumor types."
Copyright (c) 2021 CercleFinance.com. All rights reserved.